Phase III, Multi-centre, Double Blind, Randomized Placebo Controlled Trial of Aspirin for Duke C and High Risk Dukes B Colorectal Cancers

Intervention1: Aspirin: 200 mg OD for 3 years
Control Intervention1: Placebo: 200 mg OD for 3 years
Primary outcome(s): 1. Disease free survival for all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer ptient sub groups)Timepoint: 3 years;Disease free survival for colon cancer (high risk Dukes B and Dukes C colon cancer)Timepoint: 3 years
Study Design: Randomized, Parallel Group, Placebo Controlled Trial
Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Participant, Investigator and Outcome Assessor Blinded